Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2008
03/13/2008WO2008028903A2 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
03/13/2008WO2008028617A1 Heteroaryl derivatives as protein kinase inhibitors
03/13/2008WO2008028531A1 Method of culturing npcs
03/13/2008WO2008012071A3 Pharmaceutical compositions of nicotine and methods of use thereof
03/13/2008WO2008007149A3 New medical use of triazine derivatives
03/13/2008WO2008001113A3 Use of wnt5a for inhibiting scarring
03/13/2008WO2007144422A3 Combination preparations comprising bifeprunox and l-dopa
03/13/2008WO2007144153A3 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
03/13/2008WO2007142811A3 Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
03/13/2008WO2007142810A3 Methods of using low-dose doxepin for the improvement of sleep
03/13/2008WO2007136845A3 Low-dose doxepin for treatment of sleep disorders in elderly patients
03/13/2008WO2007135527A3 Benzimidazolyl compounds
03/13/2008WO2007135123A3 Mirtazapine for the treatment of neuropathic pain
03/13/2008WO2007130820A3 Mglur5 modulators i
03/13/2008WO2007119108A3 Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
03/13/2008WO2007082914A3 Method of diagnosis and method of treatment
03/13/2008WO2007064917A3 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
03/13/2008WO2001028491A3 Method and composition for the treatment of dermatologic diseases
03/13/2008US20080064853 Nervous system protein for use in treatment and prevention of nervous system and seizure disorders
03/13/2008US20080064748 Substituted enaminones, their derivatives and uses thereof
03/13/2008US20080064744 Reduced gastrointestinal side effects of analgesic opioid therapy
03/13/2008US20080064739 Creatine pyroglutamic acid salts and methods for their production and use in individuals
03/13/2008US20080064738 Neuroprotectants; preservation of cognitive activity in aging, neurodegenerative disease, reperfusion insult, ischemic brain infarction and cerebral ischemia; hydrosolubility, stability
03/13/2008US20080064728 Heterocyclic Compounds Useful as Dpp-Iv Inhibitors
03/13/2008US20080064727 Crystalline forms of tiagabine hydrochloride
03/13/2008US20080064725 Intrathecal administration of triptan compositions to treat non-migraine pain
03/13/2008US20080064724 Composition Comprising Methylphenidate and Another Drug
03/13/2008US20080064720 Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate
03/13/2008US20080064719 Crf Receptor Antagonists And Methods Relating Thereto
03/13/2008US20080064712 17-allyl-4,5 alpha -epoxy-3-methoxy-14 beta -(3-phenylpropyloxy)morphinan-6-one with various substituents in Position 3 show higher analgesic activity than their 14-hydroxy analogues; opioid antagonists
03/13/2008US20080064709 Methods and compositions for the treatment of vascular depression
03/13/2008US20080064706 Piperidine Derivatives as Histamine H3 Receptor Ligands
03/13/2008US20080064703 Fused bicycloheterocycle substituted quinuclidine derivatives
03/13/2008US20080064699 Novel compounds as cannabinoid receptor ligands and uses thereof
03/13/2008US20080064695 Neuronal nicotinic acetylcholine receptor modulators; such as ethyl 1-[4-(aminosulfonyl)phenyl]-5-(4-bromophenyl)-2-methyl-1H-pyrrole-3-carboxylate
03/13/2008US20080064690 Neuropathic or inflammatory pain relief; inhibiting ion flux through channel including PN3 subunit; potency
03/13/2008US20080064688 Anti-inflammatory medicaments
03/13/2008US20080064687 Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea
03/13/2008US20080064684 Sub-type selective serotonin receptor agonists; antidepressants; schizophrenia, Alzheimer's Disease, Parkinson's Disease; alkylation or amidation of the heterocyclylbenzazole with an alkylhalide or acylhalide
03/13/2008US20080064678 N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators
03/13/2008US20080064676 Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity
03/13/2008US20080064671 Combinations containing a 4-acylaminopyridine derivative
03/13/2008US20080064670 Including Premenstrual Dysphoric Disorder; administering ethinyl estradiol and levonorgestrel in combination for 81 to 89 consecutive days followed by only ethinyl estradiol for 7 consecutive days and an antidepressant intermittantly administered
03/13/2008US20080064668 Carbon 20 is substituted with methyl or cyclopropyl, carbon 16 is a single or double bond, and carbon 23 is a single, double, or triple bond; side effect reduction; vitamin deficiency; anticarcinogenic antiarthritic agents; immunotherapy; metabolic disorders; gene expression inhibition of ILT3
03/13/2008US20080064661 Dihydroxyl compounds and compositions for cholesterol management and related uses
03/13/2008US20080064653 A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines
03/13/2008US20080064650 Therapeutic uses of inhibitors of RTP801L
03/13/2008US20080064642 Excellent receptivity, pharmacokinetics, enzyme resistance with capability to significantly prevent and treat conditions wherein BKB1Rs are induced and over-expressed
03/13/2008US20080064638 Proteins related to schizophrenia and uses thereof
03/13/2008US20080063725 Reservoir type, modified release of active principle; crush resistant; resists immediate dose dumping in ethanol; prevents abuse, misuse, drug addiction related behavior with stupefacients, analgesics or narcotics; microparticles coated with water-insoluble cellulose derivatives, nitrogenous copolymers
03/13/2008US20080063720 Delivery System
03/13/2008US20080063719 Pharmaceutical Compositions
03/13/2008US20080063709 Trisecting, quadrisecting, and a pentasecting score pattern in or on a tablet; psychotherapeutic doxepin hydrochloride; enhanced dosage flexibility
03/13/2008US20080063702 Liposomal Formulations Comprising an Amphipathic Weak Base Like Tempamine for Treatment of Neurodegenerative Conditions
03/13/2008US20080063660 inducing specific anti-drug antibodies using drug conjugated immunogen (bacterial toxoid) to reduce a drug's toxicity; drug is cocaine, nicotine, heroin, opium, morphine, marijuana, or antineoplastic; immunogen induces production of antibodies which sequester a subsequently administered drug; drug abuse
03/13/2008US20080063635 Stabilized Human Igg4 Antibodies
03/13/2008US20080063631 prophylaxis of vascular system disorders in mammals by administering apoptotic cells and/or bodies derived from leukocytes or lymphocytes
03/13/2008US20080063600 use of deactivated lymphocytes, antibodies, drug mixtures and adjuvants, for the treatment or prevention of Cruetzfield-Jacobs disease in humans or animals; immunology; bioassays
03/13/2008US20080063599 Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
03/13/2008CA2663091A1 Modulators of interleukin-1 receptor-associated kinase
03/13/2008CA2662715A1 Method of treating peripheral nerve disorders
03/13/2008CA2662491A1 Combinations containing a 4-acylaminopyridine derivative
03/13/2008CA2662112A1 Imidazole derivatives and their use as cannabinoid type 2 (cb2) receptor modulators
03/13/2008CA2662031A1 Heteroaryl derivatives as protein kinase inhibitors
03/13/2008CA2661992A1 Pyrazolopyridine derivative and phosphodiesterase (pde) inhibitor containing the same as active ingredient
03/13/2008CA2661975A1 Benzothiazepines as antagonists for the mitochondrial sodium-calcium exchanger
03/13/2008CA2659037A1 Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
03/12/2008EP1897950A2 Human GIL-19/AE289 proteins and polynucleotides encoding same
03/12/2008EP1897948A1 Mammalian transforming growth factor beta 9
03/12/2008EP1897937A1 Method of culturing NPCs
03/12/2008EP1897881A2 Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
03/12/2008EP1897880A1 1,3-benzothiazinone derivative and use thereof
03/12/2008EP1897876A2 Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
03/12/2008EP1897867A1 Compounds, preparation process, and uses thereof used for interrupting reuptake of 5-hydroxytryptamine and norepinephrine or treating diseases such as depression et al.
03/12/2008EP1897555A2 Supplemented OMV vaccine against meningococcus
03/12/2008EP1897552A1 Polymer-conjugated glycosylated neublastin
03/12/2008EP1897546A1 Combined compositions comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
03/12/2008EP1897543A1 Buprenorphine- wafer for drug substitution therapy
03/12/2008EP1897441A1 TGF-alpha polypeptides, functional fragments and methods of use therefor
03/12/2008EP1896588A1 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF
03/12/2008EP1896489A1 Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof
03/12/2008EP1896478A2 Aspartyl protease inhibitors
03/12/2008EP1896477A1 Aspartyl protease inhibitors
03/12/2008EP1896469A2 Fused bicycloheterocycle substituted quinuclidine derivatives
03/12/2008EP1896468A1 3 -aryloxy- 8 -aza-bicyclo [3.2.1.] oct- 6- ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/12/2008EP1896467A2 Tricyclic opioid modulators
03/12/2008EP1896464A1 Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
03/12/2008EP1896463A2 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
03/12/2008EP1896459A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
03/12/2008EP1896458A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
03/12/2008EP1896457A1 New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
03/12/2008EP1896454A1 AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR -SECRETASE MODULATION
03/12/2008EP1896448A1 AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
03/12/2008EP1896428A1 Pyrimidine derivatives for the treatment op gaba b mediated nervous system disorders
03/12/2008EP1896427A2 Novel 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
03/12/2008EP1896418A1 Quinoline 3 -sulfonate esters as nk3 receptor modulators
03/12/2008EP1896416A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
03/12/2008EP1896415A1 Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
03/12/2008EP1896410A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
03/12/2008EP1896409A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors useful for the treatment of hyperlipidaemic conditions